A phase 1/2 trial of enzastaurin and erlotinib in patients with advanced solid tumors and non-small cell lung cancer (NSCLC) after prior chemotherapy.

Trial Profile

A phase 1/2 trial of enzastaurin and erlotinib in patients with advanced solid tumors and non-small cell lung cancer (NSCLC) after prior chemotherapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Enzastaurin; Erlotinib
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 01 Nov 2013 Planned end date changed from 1 Sep 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 12 Jun 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top